Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Vaccine Candidate For C. Difficile

A complex hexasaccharide found in the pathogen’s cell wall is the basis of a possible life-saving vaccine

by Sarah Everts
June 6, 2011 | A version of this story appeared in Volume 89, Issue 23

[+]Enlarge
This hexasaccharide is the proposed basis of a vaccine against C. difficile.
This hexasaccharide is the proposed basis of a vaccine against C. difficile.

When the pathogen Clostridium difficile attacks, it populates up to 40% of the human gut and produces a wide array of toxins that cause diarrhea, inflammation, and sometimes death. Scientists have now developed a vaccine candidate against this culprit of many hospital-based infections (Chem. Biol., DOI: 10.1016/j.chembiol.2011.03.009). To do so, researchers led by Peter H. Seeberger of the Max Planck Institute of Colloids & Interfaces, in Potsdam, Germany, first synthesized a complex hexasaccharide that is found in C. difficile’s cell wall. They found that C. difficile-infected mice and humans produce antibodies that recognize this sugar, suggesting that it’s a viable basis for a vaccine. The team then appended the hexasaccharide to a protein called CRM197, because sugars alone don’t elicit a strong enough immune response to build protecting antibodies (C&EN, May 30, page 53). Seeberger’s team next plans to test whether the vaccine protects mice against infection, and they aim to raise funds for a clinical trial to further develop a C. difficile vaccine for humans, which has remained elusive.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.